Oseltamivir (has known by its brand name 'Tamiflu') is a prodrug, requiring 
ester hydrolysis for conversion to the active form, Oseltamivir carboxylate. 
Oseltamivir was the first orally active neuraminidase inhibitor commercially 
developed by US based Gilead Sciences and is currently marketed by F. 
Hoffmann-La Roche (Roche). Oseltamivir is an antiviral drug which works by 
blocking the function of the viral neuraminidase protein. US FDA approved 
Oseltamivir for prophylaxis of uncomplicated influenza A and B. Currently, 
Oseltamivir is the only first line defense drug available for the treatment of 
Swine Flu. Orally Oseltamivir is well tolerated and effective in treatment of 
influenza in adolescents and adults, including the elderly and patients with 
chronic cardiac and/or respiratory disease. Many of the pharmaceutical companies 
targeted Oseltamivir as a block buster molecule. In present review, we have 
tried to cover chemistry, mode of binding, total synthesis, current patent 
status, adverse effect and clinical status of Oseltamivir giving emphasis on 
medicinal chemistry aspect.